Yüklüyor......
Cardiovascular benefits of sodium-glucose cotransporter 2 inhibitors in diabetic and nondiabetic patients
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) were developed as antidiabetic agents, but accumulating evidence has shown their beneficial effects on the cardiovascular system. Analyses of the EMPA-REG OUTCOME trial (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Pa...
Kaydedildi:
| Yayımlandı: | Cardiovasc Diabetol |
|---|---|
| Asıl Yazarlar: | , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
BioMed Central
2021
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8028072/ https://ncbi.nlm.nih.gov/pubmed/33827579 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12933-021-01266-x |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|